NCT00689052终止2 期
A Randomized, Double-blind, Placebo-controlled, Dose Titration Efficacy and Safety Study of Pramipexole ER (0.75 to 4.5 mg) Administered Orally Once Daily Versus Placebo Over a 16-week Maintenance Phase in Patients Diagnosed With Fibromyalgia, as Assessed by the American College of Rheumatology (ACR) Criteria Followed by a 24-week Open-label Extension Phase
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 61
- 试验地点
- 42
- 主要终点
- The Change in the Weekly Mean of the 24-hour Average Pain Score From a Daily Diary as Measured by the 11-point Likert Pain Scale
研究概览
简要总结
The primary objective of this study is to assess the efficacy and safety of an extended-release (ER) formulation of pramipexole in comparison with placebo for the treatment of fibromyalgia.
The objective of the open-label phase is to assess the safety profile and effect of Pramipexole (PPX) extended-release (ER) in fibromyalgia patients over a 24-week period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female outpatients greater than or equal to 18 years of age
- •Meet criteria for primary fibromyalgia as defined by the American College of Rheumatology (ACR): widespread aching pain in all four quadrants of the body and axial skeleton for greater than 3 months duration and greater than or equal to 11 of 18 tender points under digital palpitation examination with an approximate force of 4 kilograms per centimeters squared (kg/cm2)
- •Pain score of greater than or equal to 4 (scored once at screening and as a weekly mean at baseline) on the 11-point Likert pain scale with 0 = no pain and 10 = worst possible pain
- •Score of greater than or equal to 4 (= moderately ill) on the Clinical Global Impression of Severity (CGI-S) at screening and at baseline
- •All females of child-bearing potential must test negative for pregnancy at Visit
- •Females of child-bearing potential (not surgically sterilized and between menarche and two years postmenopausal) must agree to utilize medically acceptable and reliable means of birth control as determined by the investigator during the study and for one month following the last dose of study medication. Examples of reliable methods include: use of hormonal contraception (oral, injectable, or subcutaneous), double-barrier method, abstinence, partner with vasectomy, or hormonal intrauterine devices
- •Educational level and degree of understanding such that the patient can communicate intelligibly with the investigator and study coordinator
- •Judged to be reliable and agree to keep all appointments for clinic visits, tests, and procedures required by the protocol
排除标准
- •Employees of Boehringer Ingelheim (BI) (that is, employees, temporary contract workers, or designees responsible for the conduct of the study)
- •Have received treatment within 30 days prior to screening with a drug that has not received regulatory approval for any indication
- •Have previously completed or withdrawn from this study or any other study investigating pramipexole.
- •Any current or previous diagnosis of psychosis, bipolar disorder, or schizoaffective disorder as assessed by the Mini International Neuropsychiatric Interview (MINI)
- •Have any primary anxiety disorder within the past year as assessed by the Mini International Neuropsychiatric Interview (MINI)
- •Have any Diagnosis of Statistical Manual of Mental Diseases, 4th Edition (DSM-IV) Axis II disorder that would interfere with protocol compliance
- •Medium or high risk of suicidality as assessed by the Mini International Neuropsychiatric Interview (MINI)
- •History of substance abuse/dependence within the past year, excluding nicotine and caffeine
- •A positive urine drug screen for any substance of abuse or excluded medication
- •Women who are pregnant or breast-feeding
- •Have pain symptoms related to traumatic injury that will interfere with the interpretation of outcome measures
- •Patients with regional pain syndromes, multiple surgeries or failed back surgery syndrome
- •A confirmed or previous diagnosis of rheumatoid arthritis, inflammatory arthritis, or infectious arthritis, or an autoimmune disease
- •Abnormal C-Reactive Protein, Anti-Nuclear Antibody (ANA), Rheumatoid factor, or Thyroid Stimulating Hormone (TSH)
- •Any serious or unstable medical or psychiatric condition or clinically significant abnormalities in labs at screening that would lead to hospitalization during the course of the study or otherwise compromise study participation
- •Have uncontrolled seizures
- •Taking any prohibited medications that cannot be discontinued at screening
- •Patients who are treatment-refractory or whose response may be compromised by disability compensation issues
- •Patients with frequent or severe allergic reactions to multiple medications
- •Prior or current treatment with pramipexole
- •Clinically significant renal disease
- •Current or previous diagnosis of malignant melanoma
- •Clinically relevant ophthalmopathy
- •Documented sleep apnea
研究组 & 干预措施
Pramipexole ER
Experimental
0.75 mg to 4.5 mg tablets of Pramipexole ER, once daily in the evening
干预措施: pramipexole ER (Drug)
Placebo
Placebo Comparator
Placebo tablets, once daily in the evening
干预措施: placebo (Drug)
结局指标
主要结局
The Change in the Weekly Mean of the 24-hour Average Pain Score From a Daily Diary as Measured by the 11-point Likert Pain Scale
时间窗: Baseline and Week 29
The 11-point Likert Pain Scale is a numerical rating scale completed by the patient that measures the intensity of pain. The intensity scores range from 0 (no pain) to 10 (worst possible pain)
次要结局
- Fibromyalgia Impact Questionnaire (FIQ) Total Score (Change From Baseline)(Baseline and Week 29)
- The Proportion of Patients "Very Much Improved" or "Much Improved" on the Patient's Global Impression of Improvement (PGI-I) 7-point Scale(Week 29 (at the end of the maintenance phase))
- The Short Form 36 (SF-36) Health Survey, Physical Functioning Subscale (Change From Baseline).(Baseline and Week 29)
- The Proportion of Patients With at Least a 30% or at Least a 50% Improvement Relative to Baseline in Pain (Assessed on the 11-point Likert Pain Scale(Baseline and Week 29)
- Hospital Anxiety and Depression Scale (HADS) (Change From Baseline).(Baseline and Week 29)
- The Short Form 36 (SF-36) Health Survey (Change From Baseline) (Excluding the Physical Functioning Subscale(PF)).(Baseline and Week 29)
- Euroqol- 5 Dimensions (EQ-5D) Survey (Change From Baseline)(Baseline and Week 29)
- Multidimensional Assessment of Fatigue (MAF) Index (Change From Baseline)(Baseline and Week 29)
- Medical Outcomes Study (MOS) Sleep Scale (Change From Baseline)(Baseline and Week 29)
- Clinical Global Impression of Severity (CGI-S Scores)(Baseline and Week 29)
- Frequency of Rescue Medication for Pain(Week 29)
- Change From Baseline in Mean Tender Point Threshold(Baseline and Week 29)
研究者
研究点 (42)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I DisorderBipolar DisorderNCT00490971Johnson & Johnson Pharmaceutical Research & Development, L.L.C.768
已完成
3 期
Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)Chronic Obstructive Pulmonary DiseaseNCT00970268AstraZeneca291
已完成
不适用
Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected PatientsDiabetes MellitusHypercholesterolemiaHypertriglyceridemiaHIV InfectionsNCT00046267National Institute of Allergy and Infectious Diseases (NIAID)30
已完成
3 期
Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial SeizuresEpilepsyNCT00848549Eisai Inc.295
进行中（未招募）
3 期
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use DisorderMethamphetamine-dependenceMethamphetamine AbuseNCT06233799National Institute on Drug Abuse (NIDA)360